ISIN | LU2389358735 |
---|---|
Valor Number | 113841301 |
Bloomberg Global ID | UBHCUPU LX |
Fund Name | UBS (Lux) Equity SICAV - China Health Care (USD) P-acc |
Fund Provider |
UBS Asset Management Switzerland AG, Zurich
Basel, Switzerland Phone: +41 61 288 75 01 E-Mail: sh-ubs-funds-feedback@ubs.com Web: www.ubs.com/fonds |
Fund Provider | UBS Asset Management Switzerland AG, Zurich |
Representative in Switzerland |
UBS Fund Management (Switzerland) AG Basel Phone: +41 61 288 49 10 |
Distributor(s) |
UBS Global Asset Management Basel Phone: +41 61 288 20 20 |
Asset Class | Equities |
EFC Category | Equity Health Care |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets) |
Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
Investment Strategy *** | The actively managed sub-fund invests mainly in shares and other equity interests of companies related to the healthcare sector domiciled in the People’s Republic of China (“PRC”) or other companies that have close economic links with the PRC. These investments contain securities listed within the PRC (onshore) or outside of the PRC (offshore). This sub-fund promotes environmental and/or social characteristics and complies with Article 8 of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector (“SFDR”). |
Peculiarities |
Current Price * | 66.67 USD | 30.09.2024 |
---|---|---|
Previous Price * | 63.03 USD | 27.09.2024 |
52 Week High * | 72.59 USD | 06.11.2023 |
52 Week Low * | 53.44 USD | 30.07.2024 |
NAV * | 66.67 USD | 30.09.2024 |
Issue Price * | 66.67 USD | 30.09.2024 |
Redemption Price * | 66.67 USD | 30.09.2024 |
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 2,847,030 | |
Unit/Share Assets *** | 38,003 | |
Trading Information SIX |
YTD Performance | -2.21% |
29.12.2023 - 30.09.2024
29.12.2023 30.09.2024 |
---|---|---|
YTD Performance (in CHF) | -2.27% |
29.12.2023 - 30.09.2024
29.12.2023 30.09.2024 |
1 month | +17.92% |
30.08.2024 - 30.09.2024
30.08.2024 30.09.2024 |
3 months | +20.56% |
02.07.2024 - 30.09.2024
02.07.2024 30.09.2024 |
6 months | +13.97% |
02.04.2024 - 30.09.2024
02.04.2024 30.09.2024 |
1 year | -1.38% |
09.10.2023 - 30.09.2024
09.10.2023 30.09.2024 |
2 years | +3.38% |
30.09.2022 - 30.09.2024
30.09.2022 30.09.2024 |
3 years | -33.33% |
02.12.2021 - 30.09.2024
02.12.2021 30.09.2024 |
5 years | - | - |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Innovent Biologics Inc | 9.18% | |
---|---|---|
Jiangsu Hengrui Pharmaceuticals Co Ltd Class A | 7.19% | |
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A | 6.84% | |
Tencent Holdings Ltd | 5.51% | |
Yunnan Baiyao Group Co Ltd Class A | 4.85% | |
BeiGene Ltd Ordinary Shares | 3.95% | |
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Class H Shares | 3.18% | |
Akeso Inc Ordinary Shares | 2.65% | |
Legend Biotech Corp ADR | 2.46% | |
BeiGene Ltd Class A | 2.37% | |
Last data update | 31.08.2024 |
TER | 2.19% |
---|---|
TER date | 31.05.2023 |
Performance Fee *** | 0.00% |
PTR | |
Max. Management Fee *** | 1.72% |
Ongoing Charges *** | 2.16% |
SRRI ***
|
|
SRRI date *** | 31.08.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |